Interim Chief Executive Officer, AirXpanders
| Role | Organisation | Sources |
|---|---|---|
| Interim Chief Executive Officer | AirXpanders | GBS Ventures (17 May 2019), GBS Ventures (8 May 2019), GBS Ventures (2 May 2019), GBS Ventures (2 Apr 2019), GBS Ventures (12 Jun 2018), GBS Ventures (27 Apr 2018), GBS Ventures (8 Jun 2016) |
Stories naming Scott Murcray. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ASX-listed medical device maker AirXpanders, headquartered in California, extends its voluntary trading suspension while reviewing financial and strategic alternatives, and postpones its 2019 annual stockholder meeting.
ASX-listed breast reconstruction device maker AirXpanders, based in California, has appointed financial services firm Cowen to review financial and strategic options; no transaction has been agreed.
ASX-listed medical device maker AirXpanders announced a restructuring cutting roughly 45% of staff and about a third of quarterly cash use, and said it is pursuing capital raising options via a preliminary SEC filing.
AirXpanders, an ASX-listed medical device maker headquartered in California, halted trading in its securities while reviewing operations, facing an expected loan covenant breach, and weighing options for a future capital raise.
Medical device maker AirXpanders appoints US industry veteran Frank Grillo as chief executive, succeeding interim leader Scott Murcray, with co-founder Barry Cheskin welcoming the hire ahead of Grillo fronting July's investor call.
AirXpanders' quarterly update: steady revenue, cost cuts and headcount reductions, Scott Murcray interim CEO while the board searches for a permanent chief, and a planned move to Australian distributors.
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.